Jun 2026 (Q2 FY26) — Aug 6, 2026
Tandem Diabetes Care Q2 FY26 — Strong Execution and Strategic Momentum
Read the full callTandem Diabetes Care earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 255 | +5.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -5.4 | +16.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -21.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
1Y: $14.75 on 15 Oct 2025 → $16.24. High $28.26 (23 Feb 2026), low $12.82 (15 May 2026).
Overview
Call summaries
Tandem Diabetes Care Q2 FY26 — Strong Execution and Strategic Momentum
Read the full callEvery analysed call
Financials
Net profit, year on year: +60% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 244 | 283 | 234 | 241 | 249 | 290 | 247 | 255 |
| Operating profit | -26 | -1 | -121 | -52 | -23 | 8 | -17 | -14 |
| Operating margin | −10.7% | −0.2% | −51.6% | −21.5% | −9.2% | 2.9% | −7.0% | −5.4% |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -23 | 0 | -122 | -58 | -25 | 5 | -20 | -21 |
| Tax rate | −2.8% | −4618.8% | −6.9% | 9.2% | 15.8% | 112.6% | −2.6% | −2.5% |
| Net profit | -23 | 1 | -131 | -52 | -21 | -1 | -20 | -21 |
| EPS ($ per share) | -0.35 | 0.01 | -1.97 | -0.78 | -0.31 | -0.01 | -0.30 | -0.31 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -600 | -625 | -659 | -635 | -729 | -952 | -1,048 | -1,253 |
| Total liabilities | 75 | 131 | 350 | 472 | 613 | 639 | 705 | 726 |
| Fixed assets | 17 | 33 | 50 | 50 | 69 | 77 | 78 | 84 |
| Investments | 87 | 125 | 390 | 553 | 444 | 409 | 369 | 202 |
| Total assets | 206 | 326 | 716 | 905 | 1,053 | 953 | 968 | 881 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8 | 42 | 25 | 111 | 50 | -32 | 24 | -10 |
| Cash from investing | -91 | -57 | -296 | -187 | 33 | -86 | -23 | 73 |
| Cash from financing | 117 | 24 | 314 | 52 | 17 | 4 | 8 | -43 |
| Net cash flow | 18 | 9 | 43 | -23 | 101 | -114 | 10 | 21 |
| Capital expenditure | -3 | -20 | -27 | -14 | -34 | -27 | -19 | -20 |
| Free cash flow | -11 | 22 | -3 | 97 | 16 | -59 | 5 | -30 |
161 filings between Nov 17, 2025 and Aug 15, 2026.
Purchases
None
No insider bought shares.
Sales
$4.4K
2 sales by 1 insider
50% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 2 gifts, 2 other filings.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Novara Mark David | — | $4.4K | Mar 17, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 15, 2026 | Morrison Susan EVP & Chief Admin. Officer | Tax withheld | 314 | $7.1K |
| Aug 15, 2026 | Kyrillos Jean-Claude EVP & Chief Operating Officer | Tax withheld | 535 | $12.2K |
| Aug 15, 2026 | Carpenter Rick EVP & Chief Technology Officer | Tax withheld | 820 | $18.6K |
| Aug 15, 2026 | Morrison Susan EVP & Chief Admin. Officer | Option exercise | 1,730 | $0 |
| Aug 15, 2026 | Sheridan John F PRESIDENT & CEO | Tax withheld | 3,044 | $69.2K |
| Aug 15, 2026 | Carpenter Rick EVP & Chief Technology Officer | Option exercise | 897 | $0 |
| Aug 15, 2026 | Carpenter Rick EVP & Chief Technology Officer | Tax withheld | 457 | $10.4K |
| Aug 15, 2026 | Morrison Susan EVP & Chief Admin. Officer | Tax withheld | 495 | $11.2K |
| Aug 15, 2026 | Sheridan John F PRESIDENT & CEO | Tax withheld | 5,055 | $114.8K |
| Aug 15, 2026 | Gasser Elizabeth Anne EVP, Chief Strategy Officer | Option exercise | 1,917 | $0 |
| Aug 15, 2026 | Gasser Elizabeth Anne EVP, Chief Strategy Officer | Tax withheld | 589 | $13.4K |
| Aug 15, 2026 | Hansen Shannon Marie EVP & Chief Legal Officer | Tax withheld | 976 | $22.2K |
| Aug 15, 2026 | Carpenter Rick EVP & Chief Technology Officer | Option exercise | 1,610 | $0 |
| Aug 15, 2026 | Morrison Susan EVP & Chief Admin. Officer | Option exercise | 1,097 | $0 |
| Aug 15, 2026 | Hansen Shannon Marie EVP & Chief Legal Officer | Tax withheld | 559 | $12.7K |
| Aug 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Option exercise | 2,624 | $0 |
| Aug 15, 2026 | Sheridan John F PRESIDENT & CEO | Option exercise | 5,982 | $0 |
| Aug 15, 2026 | Gasser Elizabeth Anne EVP, Chief Strategy Officer | Option exercise | 1,097 | $0 |
| Aug 15, 2026 | Hansen Shannon Marie EVP & Chief Legal Officer | Option exercise | 1,917 | $0 |
| Aug 15, 2026 | Gasser Elizabeth Anne EVP, Chief Strategy Officer | Tax withheld | 1,029 | $23.4K |
| Aug 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Tax withheld | 537 | $12.2K |
| Aug 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Option exercise | 1,496 | $0 |
| Aug 15, 2026 | Hansen Shannon Marie EVP & Chief Legal Officer | Option exercise | 1,097 | $0 |
| Aug 15, 2026 | Sheridan John F PRESIDENT & CEO | Option exercise | 9,934 | $0 |
| Aug 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Tax withheld | 942 | $21.4K |
| Aug 15, 2026 | Kyrillos Jean-Claude EVP & Chief Operating Officer | Option exercise | 1,010 | $0 |
| Jul 15, 2026 | Kyrillos Jean-Claude EVP & Chief Operating Officer | Tax withheld | 1,926 | $29.4K |
| Jul 15, 2026 | Kyrillos Jean-Claude EVP & Chief Operating Officer | Option exercise | 3,636 | $0 |
| Jun 2, 2026 | Gasser Elizabeth Anne EVP, Chief Strategy Officer | Gift | 7,160 | $0 |
| Jun 2, 2026 | Gasser Elizabeth Anne EVP, Chief Strategy Officer | Gift | 7,160 | $0 |
| May 21, 2026 | Allen Dick Insider | Option exercise | 8,759 | $0 |
| May 21, 2026 | Howell Peyton R Director | Option exercise | 8,759 | $0 |
| May 21, 2026 | ROBERTSON REBECCA B Director | Option exercise | 8,759 | $0 |
| May 21, 2026 | McGroddy-Goetz Kathleen Director | Option exercise | 8,759 | $0 |
| May 21, 2026 | Cha Myoungil Director | Option exercise | 8,759 | $0 |
| May 21, 2026 | TWOMEY CHRISTOPHER J Director | Option exercise | 8,759 | $0 |
| May 21, 2026 | Malagueira Joao Paulo Falcao Director | Option exercise | 8,759 | $0 |
| May 21, 2026 | Sodhi Rajwant Director | Option exercise | 8,759 | $0 |
| May 15, 2026 | Sheridan John F PRESIDENT & CEO | Option exercise | 5,472 | $0 |
| May 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Award | 1,336 | $14.6K |
| May 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Tax withheld | 3,766 | $48.3K |
| May 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Tax withheld | 537 | $6.9K |
| May 15, 2026 | Novara Mark David EVP & CHIEF COMMERCIAL OFFICER | Tax withheld | 7,854 | $100.7K |
| May 15, 2026 | Novara Mark David EVP & CHIEF COMMERCIAL OFFICER | Option exercise | 10,496 | $0 |
| May 15, 2026 | Novara Mark David EVP & CHIEF COMMERCIAL OFFICER | Tax withheld | 57 | $731 |
| May 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Option exercise | 10,496 | $0 |
| May 15, 2026 | Novara Mark David EVP & CHIEF COMMERCIAL OFFICER | Option exercise | 76 | $0 |
| May 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Option exercise | 1,496 | $0 |
| May 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Tax withheld | 540 | $6.9K |
| May 15, 2026 | Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER | Option exercise | 1,503 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow TANDEM DIABETES CARE INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading